Panitumumab

Drug Profile

Panitumumab

Alternative Names: ABX-EGF; Anti-EGFR monoclonal antibody - Abgenix; E7.6.3; Panitumab; rHuMAb-EGFr; Vectibix

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Phase II Bladder cancer; Breast cancer; Neuroendocrine tumours; Rectal cancer
  • Phase I Solid tumours
  • Discontinued Head and neck cancer; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 19 Sep 2017 Takeda completes the phase II SAPPHIRE trial for Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (NCT02337946)
  • 05 Jul 2017 Launched for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (IV)
  • 29 Jun 2017 US FDA approves panitumumab for wild-type RAS metastatic Colorectal cancer (First-line therapy, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top